Taken together, the above results show that abnormalities of m6A modification-related enzymes represented by ALKBH5 may be a potential condition for the development, recurrence and drug resistance of ALL, which provides a novel research direction for its clinical diagnosis and treatment. This evidence concerns the gene ALKBH5 and acute lymphoblastic leukemia.